Rapamycin: one drug, many effects.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24508508.
- Also identified by DOI 10.1016/j.cmet.2014.01.001 and PMC identifier 3972801.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The mammalian target of rapamycin (mTOR) signaling pathway is a master regulator of cell growth and metabolism. Deregulation of the mTOR pathway has been implicated in a number of human diseases such as cancer, diabetes, obesity, neurological diseases, and genetic disorders. Rapamycin, a specific inhibitor of mTOR, has been shown to be useful in the treatment of certain diseases. Here we discuss its mechanism of action and highlight recent findings regarding the effects and limitations of rapamycin monotherapy and the potential utility of combination therapy with rapamycin.
Medical subject headings
- Signal Transduction
- Sirolimus
- TOR Serine-Threonine Kinases